Please assess the completion status of the following clinical trial:

Trial Title: Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Willing and able to provide informed consent~2. Age ≥ 18 years~3. High-risk resectable urothelial cancer (upper urinary tract allowed) defined as stage III UC:~cT3-4aN0M0 OR cT1-4aN1-3M0 4. Refusal of neoadjuvant/induction cisplatin-based chemotherapy or patients in whom neoadjuvant cisplatin based therapy is not appropriate.~5. World Health Organization (WHO) performance Status 0 or 1. 6. Urothelial cancer is the dominant histology (\>70%). 7. Formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks from diagnostic TUR available (or any other FFPE tumor specimens for upper tract tumors).8. Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Neutrophils ≥1.0x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, GFR\>30 ml/min, AST ≤ 2.5 x ULN, ALT ≤2.5 x ULN, Bilirubin ≤1.5 X ULN 9. Negative pregnancy test within 2 weeks of Day 1 Cycle 1 for female patients of childbearing potential.~10. For female patients of childbearing potential to use a highly effecting form(s) of contraception (i.e. one that results in a low failure rate \[\<1% per year\] when used consistently and correctly) and to continue its use for 180 days after the last dose of immunotherapy Adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms, oral contraceptives, intra-uterine device.~Exclusion Criteria:~1. Subjects with active autoimmune disease in the past 2 years. Patients with diabetes mellitus, properly controlled hypothyroidism or hyperthyroidism, vitiligo, psoriasis or other mild skin disease can still be included.~2. Documented history of severe autoimmune disease (e.g. inflammatory bowel disease, myasthenia gravis).~3. Prior CTLA-4 or PD-1/PD-L1-targeting immunotherapy.~4. Known history of Human Immunodeficiency Virus, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA), active tuberculosis, or other active infection requiring therapy at the time of inclusion.~5. Underlying medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of adverse events~6. Medical condition requiring the use of immunosuppressive medications, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) will be allowed.~7. Use of other investigational drugs before study drug administration~8. Malignancy, other than urothelial cancer, in the previous 2 years, with a high chance of recurrence (estimated \>10%). Patients with low risk prostate cancer (defined as Stage T1/T2a, Gleason score~   ≤ 6, and PSA ≤ 10 ng/mL) who are treatment-naive and undergoing active surveillance are eligible.~9. Pregnant and lactating female patients.~10. Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.~11. Severe infections within 4 weeks prior to enrolment in the study including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.~12. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to enrolment, unstable arrhythmias, or unstable angina.~13. Previous intravenous chemotherapy for bladder cancer. Prior chemoradiation is allowed.~14. Patients in whom use of a colon segment for urinary diversion is planned

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Ipi + Nivo (Type: EXPERIMENTAL): * Day 1: Ipilimumab 3 mg/kg i.v.~* Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~* Day 43: Nivolumab 3 mg/kg i.v.
- Cohort 2a: high-Ipi + low-Nivo (Type: EXPERIMENTAL): * Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~* Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~* Day 43: Nivolumab 3 mg/kg i.v.~* Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84
- Cohort 2b: low-Ipi + high-Nivo (Type: EXPERIMENTAL): * Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~* Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~* Day 43: Nivolumab 3 mg/kg i.v.~* Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete